More tools:
Markets
·
Screener
·
Research
·
Chat
Aktis Oncology, Inc. Common stock (AKTS) Financial Statements
Aktis Oncology, Inc. Common stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00ZQS8L07
XNAS · usd
24.06
▼ 0.96 (-3.84%)
As of 2026-09-09
1M
6M
1Y
Valuation
Market Cap
$1.3B
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
25.02
Day's Range
24.03 – 26.00
52-Week Range
14.56 – 34.19
Volume
375.4K
Avg Volume
280.0K
Share Statistics
Shares Outstanding
55.6M
Employees
79
Exchange
XNAS
Listed
2026-01-09
Share count as of July 31, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about Aktis Oncology, Inc. Common stock (AKTS)
What is Aktis Oncology, Inc. Common stock's Market Cap?
Aktis Oncology, Inc. Common stock's Market Cap is $1.3B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Revenue:
Collaboration revenue
3,384.0
3,227.0
Operating expenses:
Research and development
25,280.0
20,036.0
General and administrative
7,003.0
5,897.0
Total operating expenses
32,283.0
25,933.0
% of revenue
954.0%
803.6%
Loss from operations
(28,899.0)
(22,706.0)
% of revenue
-854.0%
-703.6%
Other income (expense):
Interest income
4,765.0
4,384.0
Other expense, net
(10.0)
(3.0)
Total other income, net
4,755.0
4,381.0
Net loss
(24,144.0)
(18,325.0)
% of revenue
-713.5%
-567.9%
Net loss per share of common stock, basic
(0.44)
(0.38)
Net loss per share of common stock, diluted
(0.44)
(0.38)